Abiraterone Tablet
Product Images NDC 0143-9597

6 FDA label images from Hikma Pharmaceuticals Usa Inc. · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Abiraterone (NDC 0143-9597). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Hikma Pharmaceuticals Usa Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Abiraterone-structure-02-04-2025.jpg (Abiraterone Structure 02 04 2025)

Abiraterone-structure-02-04-2025.jpg (Abiraterone Structure 02 04 2025)
Chemical structure diagram of abiraterone acetate, showing its molecular framework with carbon, hydrogen, nitrogen, and oxygen atoms arranged in a complex polycyclic steroid-like structure.*
FDA Label Image

Figure-1-02-05-2025.jpg (Figure 1 02 05 2025)

Figure-1-02-05-2025.jpg (Figure 1 02 05 2025)
A Kaplan-Meier survival curve chart depicting percentage survival over time to death in months for Abiraterone acetate tablet versus placebo. The solid line represents Abiraterone acetate tablet, and the dashed line represents placebo. Both groups show decreasing survival percentages over approximately 20 months, with patient counts at various time points listed below the x-axis for each group.*
FDA Label Image

Figure-2-02-08-2025.jpg (Figure 2 02 08 2025)

Figure-2-02-08-2025.jpg (Figure 2 02 08 2025)
A Kaplan-Meier survival curve chart displaying the percentage of subjects without death over time in months from randomization. Two groups are compared: Abiraterone Acetate Tablet and Placebo, with survival rates tracked up to 60 months. The chart includes numbers at risk for each group at multiple time points along the x-axis.*
FDA Label Image

Figure-3-02-05-2025.jpg (Figure 3 02 05 2025)

Figure-3-02-05-2025.jpg (Figure 3 02 05 2025)
A Kaplan-Meier survival curve chart showing the percentage of subjects without radiographic progression of death over months from randomization. Two groups are compared: Abiraterone Acetate Tablets and Placebo. The chart includes a survival curve for each group and a table below showing number of subjects at risk at different time points.*
FDA Label Image

Figure-4-02-05-2025.jpg (Figure 4 02 05 2025)

Figure-4-02-05-2025.jpg (Figure 4 02 05 2025)
A Kaplan-Meier survival curve chart depicting the percentage of subjects without death over time in months from randomization. Two groups are compared: Abiraterone acetate and Placebo. The chart includes the number of subjects at risk at various time points and shows a trend of higher survival in the Abiraterone acetate group compared to Placebo throughout the period up to 72 months.*
FDA Label Image

Bl-ndc-0143-9597-21-120tabs (Abiraterone Acetate Tablets 6)

Bl-ndc-0143-9597-21-120tabs (Abiraterone Acetate Tablets 6)
Label for Abiraterone Acetate Tablets USP 250 mg, showing a package containing 120 tablets. The label includes a warning about handling by women who are or may be pregnant, storage instructions, and manufacturer details listing The Arab Pharmaceuticals Manufacturing Company and distribution by West-Ward Pharmaceuticals Corp. The label also displays a barcode and NDC 0143-9597.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.